Document is current
Any future updates will be listed below
-
Authors
Trinder, Sarah M. https://orcid.org/0000-0002-2474-8166
Ziegler, David S. https://orcid.org/0000-0001-7451-7916
Lau, Loretta M. S. https://orcid.org/0000-0002-3172-0970
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (APP2019056, APP2017898, APP2018642)
Cancer Institute NSW (TPG2037, 2021/TPG2112)
Zero Childhood Cancer Program
University of New South Wales
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 11 September 2025
First Online: 27 September 2025
Declarations
:
: S.M.T has no financial interests to declare. D.S.Z is funded by a National Health and Medical Research Council (NHMRC) Synergy Grant (no. APP2019056), an NHMRC Leadership Grant (no. APP2017898) and a Cancer Institute of New South Wales (CINSW) Program Grant (no. TPG2037). L.M.S.L is funded by a CINSW Program Grant (no. 2021/TPG2112), NHMRC Synergy Grant (no. APP2018642) and the Zero Childhood Cancer Program.
: S.M.T. and L.M.S.L declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. D.S.Z. reports consulting/advisory board fees from Norgine, Medison Pharma, Amgen and Roche. D.S.Z. is an Editorial Board member of Targeted Oncology. D.S.Z. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated or analysed during the current study
: Not applicable.
: All authors contributed to the study conception and design. The first draft of the manuscript was written by S.M.T., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
